Month: May 2026
Cannabis reclassification removes some hurdles for industry
The reclassification of cannabis as a Schedule III substance is meant to remove barriers for researchers but its effects could…
What we know—and what we don’t—about marijuana’s health effects
Marijuana is far from a “silver bullet” for various illnesses, but it has some promising applications, scientists say …
Automation could transform cannabis industry
Automated kiosks could soon redefine cannabis retail, with industry leaders suggesting even customer-facing roles such as budtenders may be replaced…
DEA clarifies synthetic cannabis component is illegal (Newsletter: May 4, 2026)
PA gov slams opponent’s legalization opposition; MD gov signs psychedelics bill; TX hemp rulings; CA eases biz transition for rescheduling…
Why Tilray’s Marijuana Rescheduling Sizzle Has Fizzled
Rescheduling does matter greatly. Moving from Schedule I to Schedule III takes marijuana out of the same league as heroin,…
Missouri Lawsuit Targets ‘Cartel’ That’s Allegedly ‘Seized Control’ Of State’s Marijuana Market
The GDF Cartel has—through a combination of price-fixing, product- and supplier-allocation agreements, and coordinated exclusionary conduct—unlawfully seized control of the…
Trump’s rescheduling of marijuana is a spark for top marijuana ETFs
After amassing enormous losses over the past five years, cannabis stocks received a much-needed shot in the arm last week…
2 Medical Marijuana Stocks to Buy Now
Trulieve Cannabis and Green Thumb Industries are already two of the top cannabis retailers in the U.S. The Department of…
Why Trump’s marijuana policy shift could reshape the cannabis industry
A quiet regulatory change on medical marijuana could mean lower taxes, fresh investment and a turning point for a sector…
Tilray Brands to expand into the US marijuana market? Why you shouldn’t count on that anytime soon
Marijuana rescheduling may have taken place in the U.S., but that doesn’t mean legalization will happen anytime soon.
Recent Comments